247 related articles for article (PubMed ID: 35154166)
1. Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell-Mediated Antitumor Activity.
Zheng H; Zheng WJ; Wang ZG; Tao YP; Huang ZP; Yang L; Ouyang L; Duan ZQ; Zhang YN; Chen BN; Xiang DM; Jin G; Fang L; Zhou F; Liang B
Front Immunol; 2022; 13():845193. PubMed ID: 35154166
[TBL] [Abstract][Full Text] [Related]
2. M
Qiu X; Yang S; Wang S; Wu J; Zheng B; Wang K; Shen S; Jeong S; Li Z; Zhu Y; Wu T; Wu X; Wu R; Liu W; Wang HY; Chen L
Cancer Res; 2021 Sep; 81(18):4778-4793. PubMed ID: 34301762
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum: Decreased expression of programmed death ligand-L1 by seven in absentia homolog 2 in cholangiocarcinoma enhances T-cell-mediated antitumor activity.
Zheng H; Zheng WJ; Wang ZG; Tao YP; Huang ZP; Yang L; Ouyang L; Duan ZQ; Zhang YN; Chen BN; Xiang DM; Jin G; Fang L; Zhou F; Liang B
Front Immunol; 2022; 13():1093403. PubMed ID: 36591292
[TBL] [Abstract][Full Text] [Related]
4. Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination.
Sun Z; Mai H; Xue C; Fan Z; Li J; Chen H; Huo N; Kang X; Tang C; Fang L; Zhao H; Han Y; Sun C; Peng H; Du Y; Yang J; Du N; Xu X
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040417
[TBL] [Abstract][Full Text] [Related]
5. WTAP-induced N
Liu QZ; Zhang N; Chen JY; Zhou MJ; Zhou DH; Chen Z; Huang ZX; Xie YX; Qiao GL; Tu XH
Cancer Sci; 2024 Jun; 115(6):1749-1762. PubMed ID: 38508217
[TBL] [Abstract][Full Text] [Related]
6. N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and PD-L1.
Li J; Xu X; Xu K; Zhou X; Wu K; Yao Y; Liu Z; Chen C; Wang L; Sun Z; Jiao D; Han X
J Exp Clin Cancer Res; 2024 Apr; 43(1):119. PubMed ID: 38641828
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
8. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
9. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y
Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544
[TBL] [Abstract][Full Text] [Related]
10. METTL14 regulates CD8
Sun C; Wang J; Li H; Liu L; Lin Y; Zhang L; Zu X; Zhu Y; Shu Y; Shen D; Wang Q; Liu Y
World J Surg Oncol; 2024 May; 22(1):128. PubMed ID: 38725005
[TBL] [Abstract][Full Text] [Related]
11. Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy.
Yuan J; Li J; Shang M; Fu Y; Wang T
Biochem Biophys Res Commun; 2021 Jul; 561():187-194. PubMed ID: 34023785
[TBL] [Abstract][Full Text] [Related]
12. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
Chen X; Xu M; Xu X; Zeng K; Liu X; Pan B; Li C; Sun L; Qin J; Xu T; He B; Pan Y; Sun H; Wang S
Mol Cancer; 2020 Jun; 19(1):106. PubMed ID: 32552762
[TBL] [Abstract][Full Text] [Related]
13. The role of m6A-mediated PD-1/PD-L1 in antitumor immunity.
Liu L; Liang L; Li H; Shao W; Yang C; Lin F; Liu J; Zhang J
Biochem Pharmacol; 2023 Apr; 210():115460. PubMed ID: 36822438
[TBL] [Abstract][Full Text] [Related]
14. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma.
Chen F; Sheng J; Li X; Gao Z; Zhao S; Hu L; Chen M; Fei J; Song Z
Biomed Pharmacother; 2024 Jun; 175():116659. PubMed ID: 38692063
[TBL] [Abstract][Full Text] [Related]
15. The role of Siah2 in tumorigenesis and cancer therapy.
Li K; Li J; Ye M; Jin X
Gene; 2022 Jan; 809():146028. PubMed ID: 34687788
[TBL] [Abstract][Full Text] [Related]
16. METTL14-mediated N
Liu Z; Sun T; Piao C; Zhang Z; Kong C
Cell Commun Signal; 2022 Mar; 20(1):36. PubMed ID: 35305660
[TBL] [Abstract][Full Text] [Related]
17. Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer Immunotherapy.
Kim SB; Hwang S; Cha JY; Lee HJ
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474186
[TBL] [Abstract][Full Text] [Related]
18. N6-methyladenosine RNA modification in PD-1/PD-L1: Novel implications for immunotherapy.
Luo P; Li S; Long X
Biochim Biophys Acta Rev Cancer; 2023 May; 1878(3):188873. PubMed ID: 36842764
[TBL] [Abstract][Full Text] [Related]
19. The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer.
Moreno P; Lara-Chica M; Soler-Torronteras R; Caro T; Medina M; Álvarez A; Salvatierra Á; Muñoz E; Calzado MA
PLoS One; 2015; 10(11):e0143376. PubMed ID: 26580787
[TBL] [Abstract][Full Text] [Related]
20. RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells.
Tsuruta N; Tsuchihashi K; Ohmura H; Yamaguchi K; Ito M; Ariyama H; Kusaba H; Akashi K; Baba E
Biochem Biophys Res Commun; 2020 Sep; 530(1):235-239. PubMed ID: 32828292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
